Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in CMML, MDS/MPN, and AML
NCT02807272Phase 2Completed
- Sponsor
- Kura Oncology
- Start
- Jan 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tipifarnib in chronic myelomonocytic leukemia (CMML), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), acute myeloid leukemia (AML), sponsored by Kura Oncology. Started Jan 2017; status: completed.
02
Drugs
tipifarnib
03
Conditions
chronic myelomonocytic leukemia (CMML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02807272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807272.